IRulya Therapeutics Inc.
IRLAHealthcare|Biotechnology|US
$31.00
+1.69 (+5.77%)
Tangible Book / Share
$17.69
Cash / Share
$18.91
About
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Stock Price
-90.3%(1Y)
1M
+5.6%
3M
+2.6%
6M
+21.1%
YTD
-95.4%
1Y
-90.3%
3Y
-83.7%
5Y
-99.1%
Pipeline Summary
8 total trials2
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2Completed: 4Not Yet Recruiting: 1No Longer Available: 1
Active Trials (2)
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05798923Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Phase 2Recruiting
Enrollment: 85 participants
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
NCT06018766Bronchiolitis Obliterans Syndrome
Phase 2Recruiting
Enrollment: 30 participants
Key Facts
Market Cap$31.5M
Employees38 (+6% YoY)
CEOBrigette Roberts
IPO DateMay 9, 2019
Beta1.33
52-Week Range$15.1 – $910
Avg Volume42,886
ExchangeNASDAQ
Websitequincetx.com
Ownership
Shares Outstanding1.0M
Recent Insider Trades
Bonuccelli Catherine M.OTHER
Oct 8, 20260 shares
Valentine James ElwoodOTHER
Oct 8, 20260 shares
Wise John DraytonOTHER
Oct 8, 20260 shares
Militello JohnOTHER
Oct 8, 20260 shares
Fandrick Keith R.OTHER
Oct 8, 20263,026 shares @ $1.81
Peers
Recent News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Oct 15, 2026 · globenewswire.com
Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker
Oct 11, 2026 · defenseworld.net
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Oct 9, 2026 · globenewswire.com
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans
Oct 7, 2026 · defenseworld.net
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Oct 6, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:16 AM